<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Esophageal high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> in situ (HGD/Tis) management is in evolution </plain></SENT>
<SENT sid="1" pm="."><plain>However, treatment decisions must be made on clinical staging, which may not reflect pathologic staging </plain></SENT>
<SENT sid="2" pm="."><plain>Long-term randomized trial information, large treatment series, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry data do not exist to guide treatment decisions </plain></SENT>
<SENT sid="3" pm="."><plain>This evaluation of esophagectomy for clinically diagnosed HGD (cHGD) serves as a reference point for future therapies </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: From a 1296-patient prospective esophagectomy database, 134 patients were diagnosed with cHGD (HGD without detectable mass at biopsy) before esophagectomy (mean age 60 Â± 10 years, 120 [90%] male, and 132 [99%] Caucasian) </plain></SENT>
<SENT sid="5" pm="."><plain>Median follow-up was 7.1 years </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Histopathologic cell type was <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in 124 (93%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>Pathologic T (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>) classification (pT) was 77 (57%) pHGD, 46 (34%) pT1a, eight (6%) pT1b, and one each (1%) indefinite for <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and pT2 </plain></SENT>
<SENT sid="8" pm="."><plain>Three (2%) had regional <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> (pT1N1M0) </plain></SENT>
<SENT sid="9" pm="."><plain>There was one hospital <z:hpo ids='HP_0011420'>death</z:hpo> (0.7%) and four <z:hpo ids='HP_0011420'>deaths</z:hpo> from <z:e sem="disease" ids="C1458156" disease_type="Neoplastic Process" abbrv="">recurrent cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Survival at 1 month, 6 months, and 5, 10, and 15 years was 99%, 97%, 96%, 94%, 82%, and 75%, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Survival was at least that of a matched population </plain></SENT>
<SENT sid="12" pm="."><plain>Older age and poor lung function predicted worse survival </plain></SENT>
<SENT sid="13" pm="."><plain>Sixteen patients developed nonesophageal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, 6.1 times greater than expected </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Despite clinical staging errors, survival following esophagectomy for cHGD is excellent </plain></SENT>
<SENT sid="15" pm="."><plain>The diagnosis of cHGD does not alter survival referenced to the matched general population; however, cHGD patients appear to be at increased risk of second nonesophageal primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>Therapy for cHGD should be patient specific, because patient and not <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> characteristics determine survival </plain></SENT>
</text></document>